Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)

被引:0
作者
Tamiya, M. [1 ]
Hata, A. [2 ]
Katakami, N. [2 ]
Kaji, R. [2 ]
Yokoyama, T. [3 ]
Toshihiko, K. [3 ]
Inoue, T. [1 ]
Kimura, H. [4 ]
Yano, Y. [4 ]
Tamuta, D. [5 ]
Morita, S. [6 ]
Negoro, S. [7 ]
机构
[1] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan
[2] Inst Biomed Res & Innovat, Integrated Oncol, Kobe, Hyogo, Japan
[3] Kurashiki Cent Hosp, Resp Med, Kurashiki, Okayama, Japan
[4] Toneyama Natl Hosp, Thorac Oncol, Toyonaka, Osaka, Japan
[5] Kobe Univ, Grad Sch Med, Resp Med, Kobe, Hyogo, Japan
[6] Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan
[7] Hyogo Canc Ctr, Med Oncol, Akashi, Hyogo, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
423P
引用
收藏
页数:1
相关论文
empty
未找到相关数据